(Pfizer) Pfizer Inc. has agreed to supply the US government with 10 million treatment courses of PAXLOVID, an oral antiviral drug candidate against Covid-19.
The treatment courses will be delivered later this year and will end in 2022. Pfizer will get $5.29 billion from the US government upon Emergency Use Authorization of the drug candidate by the US Food and Drug Administration.
Pfizer is also working with other global regulators to offer the antiviral drug. The biotech has in place a voluntary license agreement with the Medicines Patent Pool to avail the treatment to 95 countries in the low to middle-income bracket.
If approved, PAXLOVID would become the first oral antiviral treatment against SARS-CoV-2.
PFE: NYSE is up +0.45% on premarket.
